Physiologically based pharmacokinetic/ pharmacodynamic (PBPK/PD) model of empagliflozin

This repository provides the empagliflozin physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model: the absorption, the tissue distribution, the hepatic and renal glucuronidation and the renal excretion of empagliflozin, and the inhibition of SGLT2, which lowers the renal threshold of glucose and increases the urinary glucose excretion. If you have any questions or problems please open an issue Funding Matthias König was supported by the Federal Ministry of Research, Technology and Space (BMFTR, Germany) within ATLAS by grant number 031L0304B and by the German Research Foundation (DFG) within the Research Unit Program FOR 5151 QuaLiPerF (Quantifying Liver Perfusion-Function Relationship in Complex Resection - A Systems Medicine Approach) by grant number 436883643 and by grant number 465194077 (Priority Programme SPP 2311, Subproject SimLivA). This work was supported by the BMBF-funded de.NBI Cloud within the German Network for Bioinformatics Infrastructure (de.NBI) (031A537B, 031A533A, 031A538A, 031A533B, 031A535A, 031A537C, 031A534A, 031A532B).